Detalhe da pesquisa
1.
Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.
Gynecol Oncol
; 163(2): 392-397, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34548162
2.
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
N Engl J Med
; 374(8): 738-48, 2016 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-26933849
3.
Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 150(1): 119-126, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29778506
4.
Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
Gynecol Oncol
; 139(1): 17-22, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26216729
5.
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
N Engl J Med
; 365(26): 2473-83, 2011 Dec 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-22204724
6.
Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.
Gynecol Oncol
; 128(3): 573-8, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23219660
7.
A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261.
Gynecol Oncol
; 127(1): 55-62, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22664059
8.
A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer.
Gynecol Oncol
; 121(1): 112-7, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21239048
9.
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Clin Cancer Res
; 26(6): 1288-1296, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31919136
10.
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
J Clin Oncol
; 37(26): 2317-2328, 2019 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31216226
11.
Disaggregation and invasion of ovarian carcinoma ascites spheroids.
J Transl Med
; 4: 6, 2006 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-16433903
12.
Hysteroscopy and cytology in endometrial cancer.
Obstet Gynecol
; 104(5 Pt 1): 1030-3, 2004 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-15516397
13.
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.
J Clin Oncol
; 32(12): 1210-7, 2014 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24637999
14.
Feasibility and morbidity of using saline filled tissue expanders to reduce radiation-induced bowel injury in patients with gynecologic malignancies.
Eur J Obstet Gynecol Reprod Biol
; 143(2): 93-7, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19195764
15.
A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.
Cancer
; 112(2): 331-9, 2008 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18058810
16.
Utility and limitations of abdominal radiotherapy in the management of endometrial carcinomas.
Gynecol Oncol
; 96(3): 635-42, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15721405
17.
Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary.
Gynecol Oncol
; 96(2): 307-13, 2005 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15661213
18.
Widespread lymph node metastases in a young woman with FIGO stage IA1 squamous cervical cancer.
Gynecol Oncol
; 97(2): 659-61, 2005 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15863175
19.
A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer.
Gynecol Oncol
; 95(2): 347-51, 2004 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-15491756
20.
A phase II evaluation of Temozolomide in patients with recurrent epithelial ovarian cancer.
Gynecol Oncol
; 93(3): 667-70, 2004 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15196862